It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5+/− B-cell precursors toward leukemia. Transcriptional profiling reveals that Myd88 is downregulated in immune-stressed pre-malignant B-cell precursors and in leukemic cells. Genetic reduction of Myd88 expression leads to a significant increase in leukemia incidence in Pax5+/−Myd88+/− mice through an inflammation-dependent mechanism. Early induction of Myd88-independent Toll-like receptor 3 signaling results in a significant delay of leukemia development in Pax5+/− mice. Altogether, these findings identify a role for innate immunity dysregulation in leukemia, with important implications for understanding and therapeutic targeting of the preleukemic state in children.
Immunological stressors are linked to the transformation of preleukemic B cells to B-cell acute lymphoblastic leukemia. Here the authors show a dysregulation of innate immune signaling in preleukemic precursor B cells and link to the development of B-cell acute lymphoblastic leukemia in a murine model.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

















1 CSIC-USAL, Campus M. de Unamuno s/n, Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Salamanca, Spain (GRID:grid.428472.f) (ISNI:0000 0004 1794 2467); Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain (GRID:grid.452531.4)
2 St. Jude Children’s Research Hospital, Department of Oncology, Memphis, USA (GRID:grid.240871.8) (ISNI:0000 0001 0224 711X)
3 Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas -Universidad Autónoma de Madrid), Immune system development and function Unit, Madrid, Spain (GRID:grid.465524.4)
4 Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain (GRID:grid.452531.4); CSIC/Universidad de Salamanca, Servicio de Citometría, Departamento de Medicina, Biomedical Research Networking Centre on Cancer CIBER-CIBERONC (CB16/12/00400), Institute of Health Carlos III, and Instituto de Biología Molecular y Celular del Cáncer, Salamanca, Spain (GRID:grid.11762.33) (ISNI:0000 0001 2180 1817)
5 Universidad Autónoma de Madrid, Department of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126)
6 Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain (GRID:grid.452531.4); Universidad de Salamanca, Departamento de Anatomía Patológica, Salamanca, Spain (GRID:grid.11762.33) (ISNI:0000 0001 2180 1817)
7 Carlos III Health Institute, Immunobiology Department, Majadahonda (Madrid), Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
8 Cancer Research Center (CSIC-USAL), Bioinformatics Unit, Salamanca, Spain (GRID:grid.11762.33)
9 Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain (GRID:grid.452531.4); Bioinformatics and Functional Genomics Research Group, Cancer Research Center (CSIC-USAL), Salamanca, Spain (GRID:grid.452531.4)
10 Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, Department of Pediatrics, Salamanca, Spain (GRID:grid.411258.b)
11 Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain (GRID:grid.452531.4); Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, Department of Pediatrics, Salamanca, Spain (GRID:grid.411258.b)
12 Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain (GRID:grid.452531.4); Universidad de Salamanca, Departamento de Cirugía, Salamanca, Spain (GRID:grid.11762.33) (ISNI:0000 0001 2180 1817)